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Burkitt lymphoma (BL) predominates in
pediatric patients, whereas diffuse large
B-cell lymphoma (DLBCL) is uncommon.
In contrast to adults, BL and DLBCL are
treated similarly in children and both enti-
ties have superior outcomes in children
compared with adults. Gene expression
profiling (GEP) and miRNA expression
profiling clearly differentiated pediatric
DLBCL from BL, forming distinct clusters
regardless of patient age. However, path-
way analysis of GEP data identified minor
differences between corresponding pedi-
atric and adult tumors. Predominance
(6:1) of the germinal center B-cell subtype
to activated B-cell subtype was found
among pediatric DLBCL. Two cases were
molecularly classified as primary medias-
tinal B-cell lymphoma. We observed fre-
quent abnormalities in 8q24 in pediatric
DLBCL, including MYC rearrangement in
31% (5 of 16) and gain or amplification in
50% (6 of 12) nonrearranged cases. MYC
rearrangement was present in 96% (23 of
24) BL cases. Array-based CGH analysis
identified abnormalities that are shared
between adult and pediatric DLBCL
(12q15, 19q13, 6q), and abnormali-
ties unique to the pediatric cases (4p14,
19q13.32, 16p11.2), suggesting dis-
tinct pathogenetic mechanisms relative
to age. Elucidation of the underlying tar-
get genes may provide insight into fac-
tors that modulate outcome and could
provide potential novel therapeutic tar-
gets with less toxicity for pediatric pa-
tients with B-cell non-Hodgkin lymphoma.
(Blood. 2012;119(16):3757-3766)
Introduction
Lymphoma is the third most frequent type of cancer in children,
accounting for approximately 15% of childhood malignancy. The
incidence of lymphoma varies from only 3% in children younger
than 5 years to 24% in 15 to 19 year olds.1-3 In children,
non-Hodgkin lymphoma (NHL) consists predominantly of mature
aggressive B-cell lymphomas, with Burkitt lymphoma (BL) being
most common in 5 to 14 year olds and diffuse large B-cell
lymphoma (DLBCL) predominating in 15 to 19 year olds.1,3
Pediatric BL and DLBCL are treated uniformly with short but
high-intensity multiagent chemotherapy regimens designed for BL.
Both entities have superior outcomes relative to adults, with overall
survival (OS) rates greater than 90%.1,4-8 Despite these advances,
intensive chemotherapy is associated with significant morbidity,
and more targeted, pathway-specific therapeutic approaches are
desirable.8,9 Although adult BL is also treated with a high-intensity
regimen, adult DLBCL is treated with R-CHOP or CHOP-like
regimens.10,11 The prognosis of adult DLBCL remains significantly
worse than DLBCL in children, but it is unclear whether this is
because of the ability of children to better tolerate intensive
treatment or whether distinct pathogenetic mechanisms modulate
disease outcome.
BL and DLBCL are recognized by the World Health Organiza-
tion (WHO) as separate entities having distinct genetic alterations,
tumor morphology, and immunophenotype. However, there is
significant overlap in the defining features of BL and DLBCL in
some cases, resulting in a group of unclassifiable lymphomas with
features intermediate between BL and DLBCL.12 Compared with
adults, pediatric DLBCL shares more features with BL, including
high proliferation, increased MYC expression, decreased BCL2
expression, higher incidence of MYC translocation, and germinal
center (GC) phenotype (75%).13,14 Delineation of homogeneous
groups of BL and DLBCL to help identify tumor-specific character-
istics therefore remains challenging. Gene expression profiling
(GEP) has been used to more precisely classify BL and DLBCL
molecularly.15,16 Using GEP-defined groups of molecular BL
(mBL), 2 previous studies found no differences in gene expression
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or DNA copy number alterations (CNAs) between pediatric and
adult mBL, despite clinical differences between these 2 groups.17-19
Comparisons of GEP and CNA between adult and pediatric
DLBCL has not been reported, however.
Genome-wide miRNA profiling has also been used to molecu-
larly define different types of lymphoma. Using 6 BL cases, 1 study
identified miRNAs differentially expressed in BL relative to
chronic lymphocytic leukemia, mantle cell lymphoma, and follicu-
lar lymphoma.20 A 9-miRNA signature was also found to differenti-
ate the activated B-cell (ABC) and GC B-cell (GCB) subtypes of
DLBCL.21 Through coordination of array CGH and miRNA
expression data, Li et al identified 63 miRNA that are deregulated
in DLBCL by recurrent copy number (CN) changes.22 These
studies underscore the contribution of miRNA deregulation in
lymphoma pathogenesis and the potential utility of miRNA profil-
ing in classifying tumors. However, miRNA profiles that distin-
guish BL and DLBCL are still unavailable, and profiling of
pediatric lymphomas has not been reported.
DLBCL is a heterogeneous group of entities both clinically and
biologically, and includes the GCB and ABC subtypes, which can
be defined molecularly by GEP.23-25 After multiagent chemo-
therapy, with or without rituximab, patients with the GCB subtype
have a significantly better OS compared with those with the ABC
subtype.23,26 Primary mediastinal large B-cell lymphoma (PMBL)
shares morphologic features with DLBCL but is now recognized as
a distinct entity that shares some features of classical Hodgkin
lymphoma.27 In contrast with other DLBCL subtypes, therapeutic
outcomes are worse for children with PMBL compared with adult
patients.28,29 By immunohistochemistry, pediatric DLBCL was
shown to consist predominantly of the GCB subtype,13,14 which
may account for the favorable prognosis in this age group.
However, a GEP-based molecular classification of pediatric
DLBCL is currently lacking.
In this study, we sought to characterize pediatric BL and
DLBCL molecularly using GEP and miRNA analysis, and to
determine whether differences in these signatures exist between
pediatric and adult tumors. Using homogeneous, molecularly
defined cohorts, we also examined whether differences in genetic
alterations or molecular pathways between adult and pediatric
tumors may explain the clinical differences and provide insight into
distinct pathogenetic mechanisms.
Methods
Patient characteristics
Pediatric specimens were collected from the Cooperative Human Tissue
Network pediatric NHL repository through the Children’s Oncology Group,
and adult specimens were collected from the Nebraska Lymphoma Study
Group Registry and Tissue Bank. Pediatric patients were defined using a
cut-off of 20 years of age or younger and adult patients were defined as
older than 20 years. Frozen tissues were obtained from 57 pediatric BL
(ages 2-20 years; median, 8 years), 13 pediatric DLBCL (ages 9-18 years;
median, 15 years), 26 adult BL (ages 21-85 years; median, 66 years), and
98 adult DLBCL (ages 22-87 years; median, 60 years). Clinical data were
available on all adult and 36 pediatric patients. Pathology review of the
pediatric cases was done by T.C.G. and W.C.C. using available materials,
which included institutional pathology reports and hematoxylin and eosin
slides, and adult cases were reviewed by a panel of Leukemia/Lymphoma
Molecular Profiling Project pathologists. GEP was done on all pediatric
(n  70) and adult (n  124) cases. This study was reviewed and approved
by the institutional review board at University of Nebraska Medical Center.
GEP
Frozen sections were cut from each of the cryopreserved blocks and
examined for adequacy of the materials before other studies. Genomic
DNA and total RNA were isolated by All prep DNA/RNA Mini Kit
(QIAGEN). GEP was done by Human Genome U133 Plus Version 2.0 array
(Affymetrix) and analyzed by BRB-ArrayTools Version 3.7 software
(http://linus.nci.nih.gov/BRB-ArrayTools.html),30 as previously described.23
Molecular classification of cases was by the Bayesian compound covariate
predictor method25 using a published gene expression signature distinguish-
ing BL from DLBCL,15 as described previously.31 A second published gene
signature that distinguishes mBL from other mature aggressive B-cell
lymphomas16 was used to confirm the BL and DLBCL molecular classifica-
tions. Cases classified as molecular DLBCL were then subclassified into
ABC, GCB, and PMBL subtypes of DLBCL.23,27 Gene set enrichment
analysis was used to compare pediatric (n  45) with adult (n  17) mBL,
and pediatric (n  13) with adult (n  51) GCB mDLBCL using the
Curated Gene Set in the Broad Institute’s Molecular Signature Database.
SNP array analysis of DNA CNAs and copy neutral LOH
Genomic DNA (250 ng) was prepared from all 21 pediatric mDLBCL
specimens according to the GeneChip Mapping 500K Assay protocol for
hybridization on 250K NspI Human Mapping Arrays (Affymetrix). Single
nucleotide polymorphism (SNP) genotypes, CN data, and regions of copy
neutral loss of heterozygosity (LOH) were generated using Genotyping
Console Version 2.1 software from Affymetrix, as previously described.31
CNAs were aligned and the minimal common region (MCR) for each
recurrent abnormality was determined. CNA occurring in more than 10% of
cases were selected for further analysis. MCRs that were devoid of genes or
that showed complete overlap with an annotated CNV of similar CN state
were excluded. Gene expression data for all RefSeq genes residing in an
MCR were compared with gene CN using the class comparison tool in BRB
ArrayTools. The criterion used to define differential gene expression
between CNA and CNA groups was P  .05 under the random variance
model univariate test.
Analysis for MYC gene rearrangement
Interphase FISH analysis for chromosome 8q24 (MYC) translocations was
performed using cryostat tissue sections, as previously described with
minor modification.32 Briefly, a MYC break-apart probe (Abbott-Vysis) was
used for hybridization. Nuclei were counterstained with 4,6-diamidino-2-
phenylindole in Antifade solution, and the slides were visualized using an
Olympus BX51 fluorescence microscope. Images were captured and
archived using CytoVision Version 4.5.2 software (Applied Imaging). A
total of 50 to 100 nuclei per case were scored for the presence of the MYC
translocation. The normal cutoff for this FISH assay in tissue sections has
been established to be 15% by prior studies.
miRNA isolation and profiling
Total RNA for miRNA profiling was extracted from four 20M sections
(based on 1 cm2 surface area) of cryopreserved tissues using the mirVana
miRNA isolation Kit according to the manufacturer’s instructions (Am-
bion). Reverse transcription was done with 300 ng of total RNA using the
Megaplex RT Primers and enzyme kit as suggested by the manufacturer
(ABI). To enhance assay sensitivity, a preamplification step of 12 cycles
was introduced using Megaplex PreAmp Primers. The preamplified cDNA
was loaded onto the 384-well format TaqMan microRNA assay plates
(TaqMan human miRNA array Version 2.0, ABI). Quantitative real-time
PCR was performed on a 7900HT Fast Real-Time PCR System (ABI).
Threshold cycle (CT) was defined as the fractional cycle number at which
the fluorescence exceeds the fixed threshold of 0.1 with automatic baseline
using the RQ Manager Version 1.2 software (ABI). The raw data were
uploaded into BRB-ArrayTools (Version 3.7.0) for analysis. Using the
expression of all miRNA, classification of BL and DLBCL cases was done
using the compound covariate Bayesian predictor, in which specimen labels
were assigned by the GEP-based molecular classifier. Classification preci-
sions were evaluated using leave-one-out cross-validation. Differential
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miRNA expression between groups was determined by random-variance
T test and significance-analysis-of-microarrays (SAM).
Clinical correlations
Fisher exact test was used to analyze categorical data, and Wilcoxon
rank-sum test was used to analyze continuous data between groups. Fisher
exact test was used to examine the association between age and GEP
predictor in DLBCL. Posthoc tests were adjusted for multiple comparisons
using the Bonferroni method. The Kaplan-Meier method was used to
estimate overall survival distributions, and the log-rank test was used to
compare survival distributions between groups. SAS Version 9.3 software
was used for data analysis (SAS Institute).
Results
Patient characteristics and molecular classification
Table 1 summarizes the pathologic and molecular classifications
and characteristics of the 70 pediatric patients. The 57 pediatric BL
patients, as determined by pathology, were predominantly male
( 80%) and had a median age at diagnosis of 8 years. The
13 pediatric DLBCL patients by pathology were also mostly male
and had a median age at diagnosis of 15 years, which was
significantly different from the BL median age (P  5  105). For
patients with a concordant molecular and pathologic diagnosis,
median age at diagnosis was 8 years for mBL and 15 years for
mDLBCL. However, mBL cases with a discrepant DLBCL patho-
logic diagnosis had a median age at diagnosis of 13 years,
significantly different from other mBL (P  .02). Similarly, mDL-
BCLs with discrepant BL pathology had a median age at diagnosis
of 6 years, significantly different from other mDLBCLs (P .0001).
Supplemental Figure 1 (available on the Blood Web site; see the
Supplemental Materials link at the top of the online article)
illustrates the significant differences in OS between pediatric and
adult cases defined molecularly by GEP. Pediatric DLBCL and BL
had OS of 100% and 90%, respectively. As expected, adult
DLBCL, whether treated with CHOP or R-CHOP, and adult BL
treated aggressively had a significantly decreased OS relative to the
pediatric cases.6 Five cases of DLBCL from the Nebraska Lym-
phoma Study Group Registry and Tissue Bank were younger than
20 years but were treated with a CHOP-like regimen similar to
adult DLBCL. Interestingly, these cases had a better OS relative to
adult DLBCL patients who were treated similarly.
Using the Bayesian prediction method, we applied a GEP-based
molecular classifier to the pediatric cases that robustly distin-
guishes BL and DLBCL in adult lymphomas.15 The predictor
identified 47 mBLs and 21 mDLBCLs with probability more than
99% (Table 1; Figure 1A). Two cases had probabilities intermediate
between BL and DLBCL and were not classifiable molecularly.
Approximately 80% of all pediatric cases had a molecular classifi-
cation consistent with the pathologic diagnosis; however,
10 morphologically defined BLs were reclassified as mDLBCL and
2 morphologically defined DLBCLs were reclassified as mBL. To
confirm the case reclassifications, we used a second, independently
derived gene signature that distinguishes mBL from other mature
aggressive B-NHL.16 Cases classified as mBL or mDLBCL were
concordant between the 2 gene signatures; however, a higher
number of cases were unclassifiable (ie, probability  90%) by
Hummel classifier,16 with the majority of these cases showing
probability of more than 70% versus more than 90% by our
classifier for the same entity.15
Subtype classification of the 21 pediatric mDLBCL specimens
was done using 2 gene signatures: a predictor that distinguishes
GCB and ABC subtypes,23 and a PMBL gene signature.27 These
classifiers identified 13 GCB, 2 ABC, 2 PMBL, and 4 nonclassifi-
able cases (Table 2). Both PMBL cases were female adolescents
with a mediastinal mass and amplification of the chromosome 2p
REL locus, as detected by array comparative genomic hybridiza-
tion. A higher proportion of the GCB subtype relative to the ABC
subtype was found, predominantly in the discrepant cases (ie, those
classified as BL by pathology and mDLBCL by GEP). The
supervised hierarchical clustering of all pediatric and adult cases
showed 2 distinct clusters of BL and DLBCL patients regardless of
patient age (Figure 1B). The pediatric and adult cases intermixed
and did not form subclusters, suggesting strong similarity of the
respective pediatric and adult tumors at the gene expression level.
Differential gene expression and pathway enrichment in adult
and pediatric lymphomas
Using molecular classification, a sufficient number of pediatric
GCB mDLBCL (n  13) and mBL (n  45) cases were available
for comparison with adult GCB mDLBCL (n 51) and adult mBL
(n  17) cases. SAM analysis identified only 132 differentially
expressed genes between adult and pediatric GCB mDLBCL
(supplemental Table 1; supplemental Figure 2) and 63 differentially
expressed genes between adult and pediatric mBL (supplemental
Table 2; supplemental Figure 3). Gene set enrichment analysis
identified pathways and gene signatures that differed significantly
between pediatric and adult tumors (Table 3). Comparison of adult
and pediatric GCB mDLBCL revealed enrichment for B-cell
surface molecules and GC markers in adult GCB cases. Genes
within these pathways that were up-regulated in adult GCB relative
to pediatric GCB included CD19, CD20, CD40, CD52, CD72,
CD79a, CD79b, CXCR5, and BLNK. Ingenuity analysis found
Table 2. Molecular subtype classification of pediatric DLBCL
Pathologic diagnosis*
Molecular diagnosis†
GCB ABC PMBL NC
DLBCL 5 1 2 3
BL 8 1 0 1
Total 13 2 2 4
NC indicates nonclassifiable cases with a diagnostic probability of  90% by
Bayesian classification.
*Pathologic diagnosis is the specimen diagnosis based on pathology review
provided by the Cooperative Human Tissue Network.
†Molecular diagnosis is the Bayesian classification of cases using 2 DLBCL
subtype gene signatures: 1 that distinguishes GCB and ABC DLBCL subtypes,23 and
a PMBL gene signature.27
Table 1. Classification of pediatric patients
Pathologic diagnosis BL (n  57) DLBCL (n  13)
Median age at diagnosis, y (range) 8 (2-20) 15 (9-18)
Sex
Female 11 3
Male 46 10
Molecular diagnosis*
mBL 45 2†
mDLBCL 10† 11
NC 2 0
NC indicates nonclassifiable cases with a diagnostic probability of  90% by
Bayesian classification.
*Molecular diagnosis is the Bayesian classification of cases using the Burkitt
Lymphoma Gene Signature derived from Dave et al.15
†Case with a molecular classification that was discrepant with the pathologic
diagnosis.
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Figure 1. Gene expression profiling of BL and DLBCL. (A) Molecular classification of pediatric lymphomas using the Bayesian compound covariate predictor method and a
published gene signature that distinguishes BL from DLBCL.15 GEPs of adult lymphomas used to derive this signature were used as a training (GEO accession no. GSE4732)
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further enrichment for pathways involved in inflammation and
altered T- and B-cell signaling in adult relative to pediatric GCB
mDLBCL. Enrichment for apoptosis pathways, BCR signaling,
and GC markers, G1 to S cell cycle transition, BCL2 family, and
PIP3, p38 MAPK, and IL-10 signaling pathways were found in
adult mBL relative to pediatric mBL. Interestingly, p38 MAPK
signaling has been shown to up-regulate IL-10 gene expression in
BL cells, in turn promoting lymphomagenesis.33 In contrast,
pediatric mBL showed enrichment for inflammatory pathways and
MYC targets relative to adult mBL tumors.
miRNA profiling
Expression profiles of 380 miRNAs were generated from a
representative sample of 46 adult mDLBCL, 12 pediatric mDL-
BCL, 13 adult mBL, and 18 pediatric mBL specimens that were
selected based on gene expression-defined molecular classification.
Comparison of mBLs and mDLBCLs identified 35 differentially
expressed miRNAs (supplemental Table 3). The 35 miRNA
signature identified by SAM analysis included 15 miRNAs highly
expressed in mBLs relative to mDLBCLs (BL signature), and
20 miRNA highly expressed in mDLBCLs relative to mBLs
(DLBCL signature). The BL signature is dominated by MYC-
regulated miRNAs, including the miR-17-92 cluster, along with the
paralogous cluster on the X chromosome (miR-18b, miR-20b, and
miR-106a). A subset of mDLBCL cases (20 of 58) showed high
expression of the BL miRNA signature, suggesting high MYC or
E2F activity. Hierarchical clustering of these 35 miRNAs segre-
gated BL and DLBCL into 2 major distinct clusters, with each
cluster containing an admixture of both pediatric and adult mBL or
mDLBCL cases (Figure 1C). Of 89 cases, only 2 adult DLBCLs
clustered with the BL cases and only one pediatric BL clustered
with DLBCL cases, confirming that these are 2 distinct entities
regardless of patient age. A subset of DLBCL cases, both pediatric
and adult, expressed high levels of both the DLBCL and BL
miRNA signatures, forming a distinct cluster of DLBCLs at the far
right of Figure 1C. Comparison of miRNA expression between
pediatric and adult tumors by SAM analysis (FDR 0.1) revealed
no significant differences in DLBCL and only a single significant
miRNA in BL, whereby miR-9 expression was 5-fold lower in
pediatric BL relative to adult BL.
MYC gene rearrangement analysis
FISH analysis was performed on all molecularly reclassified and
concordant DLBCL cases that we had sufficient materials for
examination. The results are shown in Table 4. Of the concordant
cases, one of 7 had MYC rearrangement, whereas the discordant
cases showed 4 of 9 evaluable cases with rearrangement. Gain or
amplification affecting the MYC locus was frequent, affecting 3 of
5 concordant and 3 of 6 discordant cases without MYC rearrange-
ment. Gain of chromosome 8 is rare in BL and pediatric
DLBCL,19,34 indicating that these changes were not the result of
whole chromosome gains. Thus, abnormalities of the MYC locus
were frequent in these pediatric DLBCL cases with rearrangement
in a total of 5 of 16 and gain or amplification in 6 of 11
nonrearranged cases. FISH and cytogenetic studies were performed
on 26 cases of BL with 24 cases having evaluable results. Of these,
23 cases (96%) had MYC rearrangement. The remaining case
showed amplification of the 8q24 locus.
Chromosomal imbalances in pediatric lymphoma
High-quality SNP data (SNP call rate  85) for DNA CN analysis
were obtained from 18 of 21 pediatric cases of mDLBCL,
including 11 GCB, 2 ABC, 2 PMBL, and 3 nonclassifiable
mDLBCL (mDLBCL-NC). To determine the spectrum of CNAs in
pediatric DLBCL, MCRs were compiled for aberrations occurring
in 2 or more cases and included 16 recurrent gains (Figure 2A) and
18 recurrent losses (Figure 2B). Supplemental Figure 2 illustrates
the genome wide aberrations for pediatric mDLBCL cases, coded
by molecular subtype. Both PMBL cases harbored a gain of 2p that
included the REL and BCL11A genes. Large aberrations previously
found in DLBCL34,35 were also observed in the pediatric cases,
including: 6q, 7/7q, 12, 17p, and 17q (supplemental
Figure 2). Losses of 19q13.32 and 4p14 minimal regions are novel
and have not been reported in other DLBCL series. Recurrent
regions of copy neutral LOH were also observed at 1q, 2, 6p, 9p,
and 19p.
Table 3. Differential pathway and gene set enrichment in adult and
pediatric tumors
Broad GeneSets
No. of
genes
P (Goeman
global test)
Enrichment in Adult mGCB relative to Ped mGCB
BASSO_GERMINAL_CENTER_CD40_UP 225 .023
TH1 TH2 PATHWAY 28 .009
CELL_CYCLE_CHECKPOINT_II 21 .022
CTLA4 PATHWAY 41 .009
TARTE_BCELL 71 .024
Enrichment in Adult mBL relative to Ped mBL
APOPTOSIS_KEGG 118 .0003
BRENTANI_DEATH 176 .002
APOPTOSIS_GENMAPP 99 .001
APOPTOSIS 168 .001
CASPASE PATHWAY 54 .0005
SA_FAS_SIGNALING 27 .002
DEATH PATHWAY 86 .002
BAD PATHWAY 60 .004
P38 MAPK PATHWAY 104 .009
ST_P38_MAPK_PATHWAY 99 .02
IL10 PATHWAY 31 .001
IL18 PATHWAY 10 .001
RAS PATHWAY 53 .016
AKT PATHWAY 32 .026
ST_JAK_STAT_PATHWAY 23 .003
KIM_TH_CELLS_UP 115 .007
ST_TUMOR_NECROSIS_FACTOR_PATHWAY 67 .009
G1_TO_S_CELL_CYCLE_REACTOME 142 .008
SIG_BCR_SIGNALING_PATHWAY 139 .005
BCR PATHWAY 98 .019
SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES 97 .003
BASSO_GERMINAL_CENTER_CD40_UP 225 .004
Enrichment in Pediatric mBL relative to Adult mBL
INFLAMMATORY_RESPONSE_PATHWAY 70 .002
MYC_TARGETS 109 .0006
Figure 1 (continued) dataset for the Bayesian predictor. Pediatric lymphomas with a probability  90% were classified accordingly. (B) Hierarchical clustering of adult
(n  21) and pediatric (n  49) BL and adult (n  102) and pediatric (n  21) DLBCL cases using the gene expression signature used in panel A demonstrated robust
distinction of BL and DLBCL regardless of patient age. Pediatric and adult specimens intermingled and did not form distinct subclusters. (C) Hierarchical clustering of BL and
DLBCL using 35 significantly differentially expressed miRNAs between BL and DLBCL. Cases clustered by entity regardless of patient age. Two adult DLBCL cases clustered
with BL and one pediatric BL case clustered with DLBCL. A separate cluster of DLBCL (far right) demonstrated high expression of both the BL and DLBCL signatures.
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Supplemental Table 4 lists all RefSeq genes residing within
each minimal region. Genes highlighted in bold demonstrated
significant correlation between DNA CN and gene expression.
However, because of small sample size and the heterogeneous
groups of cases, only a small number of genes showed clear
correlation of expression with gene CN. Extended MCRs, which
included an additional 1 Mb on either side of the minimal region,
were also examined. Table 5 lists candidate genes for select
extended MCRs based on putative gene/protein function and/or
correlation of gene expression with DNA CN (bolded genes).
Discussion
In this study, we performed molecular profiling of a cohort of
pediatric aggressive B-cell NHLs, including 57 BL and 13 DLBCL
defined by morphology. Pediatric patients with NHL have a
significantly better prognosis than adult patients with the same
histologic subtype,8 a finding that was also observed in this study
(supplemental Figure 1). Between the ages of 15 and 29 years, the
predominant histologic subtype shifts from BL to DLBCL, transi-
tioning from a childhood to an adult NHL spectrum.1,3 Despite this
shift in incidence, adolescent DLBCL patients in the 15- to 20-year
age range fare better when treated with more aggressive regi-
mens.4,7 Accordingly, 5 DLBCL cases within the 15- to 20-year age
range in this study had been treated similar to adult DLBCL
patients, receiving a CHOP-like regimen, and showed significantly
decreased OS relative to pediatric DLBCL receiving aggressive
therapy (supplemental Figure 1). Additional cases need to be
studied to discern whether this reflects a true change in biology or
merely a better prognosis with younger age and more aggressive
treatment.
Identifying a homogeneous patient population is important in
studying underlying tumor biology, yet the distinction between BL
and DLBCL remains a diagnostic challenge. The 2008 WHO
classification includes a provisional category of B-cell lymphoma,
unclassifiable, with features intermediate between DLBCL and BL,
to account for the significant number of cases with morphologic,
immunophenotypic and cytogenetic features intermediate between
BL and DLBCL.12 In contrast to adults, pediatric DLBCL have
been reported to demonstrate moderate to high proliferation rates
(83%), increased MYC protein expression (84%), a higher inci-
dence of MYC translocation (37%),36 and an increased frequency of
the GC phenotype (75%), suggesting greater similarity between the
molecular features of DLBCL and BL in pediatric cases.13 GEP has
been used to more precisely classify BL and DLBCL both in
adults15,16,37 and children.17-19,34 Using our molecular signatures to
distinguish BL and DLBCL, we observed an approximate 20%
reclassification rate for both morphologic BL (10 of 57 mDLBCL)
and DLBCL (2 of 13 mBL). We also examined our cases with the
Hummel classifier,16 and cases classified as mBL or mDLBCL are
in complete concordance with our cases, but there are more
unclassifiable cases using their classifier. The relatively high rate of
reclassification for childhood cases may be the result of an increase
in cases with overlapping features in pediatric BL and DLBCL,
particularly the higher incidence of MYC deregulation and in-
creased proliferation in childhood DLBCL. MYC rearrangement
studies indeed demonstrated a higher incidence of rearrangement in
childhood DLBCL than adult cases, consistent with Poirel et al,34
findings that showed Myc rearrangement in 33% of pediatric
DLBCLs.34 In addition, there was also a high incidence of gain or
amplification in the MYC locus supporting that deregulated expres-
sion of the MYC gene may be a prominent feature of pediatric
DLBCL. The study of pediatric DLBCL and BL by Klapper et al
reclassified a large number of cases, but there was more reclassifi-
cation of DLBCL into mBL than in the reverse direction.17 There
was also a lower incidence of MYC rearrangement in the mDLBCL
cases. The differences with our series could be partly the result of
the different tendency of classification by pathologists of the
2 tumors in the United States. The incidence of MYC rearrangement
is higher in our mDLBCL cases, which may be partly related to the
limitations inherent to the rather small number of cases in both
series. There were also a larger number of unclassifiable cases in
the series by Klapper et al,17 and some of these cases could have
been classified into a specific category by our diagnostic algorithm.
These issues need to be addressed in the future by studying a large series
Table 4. Myc rearrangement and gain/amplification in pediatric DLBCL
Case ID Pathologic diagnosis
Molecular diagnosis by GEP
BL vs DLBCL DLBCL subgroup Age, y Sex t(8;14) 8q24 CN
P01 DLBCL DLBCL GCB 9 M  3-4
P02 DLBCL DLBCL GCB 10 M  3-5
P03 DLBCL DLBCL GCB 13 M  3-4
P04 DLBCL DLBCL GCB 18 F  ND
P05 DLBCL DLBCL PMBL 15 F  2
P06 DLBCL DLBCL UC 11 M  2
P07 DLBCL DLBCL UC 18 M  3-4
P08 BL DLBCL ABC 2 M  2
P09 BL DLBCL UC 11 F  3
P10 BL DLBCL GCB 6 M  ND
P11 BL DLBCL GCB 4 F  2
P12 BL DLBCL GCB 10 M  2
P13 BL DLBCL GCB 10 F  3-4
P14 BL DLBCL GCB 2 M  2
P15 BL DLBCL GCB 5 M  3
P16 BL DLBCL GCB 6 M ND Amplification
P17 BL DLBCL GCB 12 M  ND
The abnormal range for MYC rearrangement is 15%-100%. The abnormal range for MYC amplification is 10%-100%. The abnormal range for multiple copies of 8q24 is
10%-100%.
UC indicates unclassifiable DLBCL; and ND, not determined.
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of cases using uniform techniques and criteria. MYC gene was rear-
ranged in the majority (96%) of mBL cases as expected. Similar
incidence has been observed in Poirel et al34 and Klapper et al.17
DLBCL cases reclassified as molecular BL showed high
expression of MYC and MYC targets, high expression of “BL-high”
GCB genes,15 and low expression of MHC-I and NF-B target
genes. Unsupervised hierarchical clustering divided mBL and
mDLBCL cases into 2 distinct clusters, providing further support
for these classifications. Pediatric and adult cases were intermixed,
demonstrating significant overlapping features within each entity
regardless of patient age. These data show that molecular classifica-
tion provides a robust means of diagnosing BL and DLBCL,
particularly in pediatric cases.
By immunohistochemical classification, pediatric DLBCL cases
show a predominance of the GCB subtype; however, unlike adult
GCB DLBCL, the t(14;18) translocation is reported to be rare or
absent.13,14 In a subsequent study, Klapper et al were not able to
demonstrate the predominance of the GCB subtype in their series
of DLBCL,17 but, using a GEP signature that distinguishes the
GCB and ABC subtypes of DLBCL,23 we found a 3:1 predomi-
nance of the GCB subtype in pediatric mDLBCL by gene
expression. However, too few cases were available to ascertain
whether the GCB subtype predominance accounts for the favorable
outcome in pediatric relative to adult DLBCL. Two female
pediatric PMBL cases were also identified using a gene signature
that distinguishes PMBL from the other DLBCL subtypes.27
Amplification of the REL locus is frequently seen in PMBL38 and
was found in both pediatric cases by array comparative genomic
hybridization.
Comparative analysis of the GEP of childhood and adult
DLBCL has not previously been undertaken. A sufficient number of
pediatric GCB cases (n 13) were available in this study for
comparison with adult GCB mDLBCL. At the gene expression
level, pediatric and adult GCB DLBCL were highly homogeneous,
differing in only 132 transcripts by SAM analysis (supplemental
Table 1). Pathway analysis revealed enrichment in expression of
B-cell surface molecules, genes involved in BCR signaling, and
altered T- and B-cell signaling pathways in adult relative to
pediatric GCB DLBCL. Enhanced antigen-independent B-cell
signaling and/or pathway alterations, which facilitate tonic BCR
signaling, may be important in B-cell survival in adult DLBCL.
Pediatric DLBCL may be less dependent on BCR signaling,
Figure 2. Pediatric mDLBCL DNA copy number alterations. Recurrent DNA CN gains (A) and losses (B) detected by array CGH in molecularly defined pediatric DLBCL.
The cytoband is listed for each MCR occurring in 2 or more patient samples. Frequency of aberration is coded according to the molecular subtype classification.
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suggesting alterations in pathways that compensate for this.
FOXO1-dependent PI3K signaling, downstream of the BCR, was
recently shown to promote survival of BCR-deficient mature
B cells.39 In GCB DLBCL, constitutive or “tonic” BCR survival
signals through BCL6 in the absence of receptor stimulation have
been shown.40,41 Further studies on BCR signaling in pediatric
DLBCL would be of interest, as too few pediatric cases were
available in the present study to ascertain preferential activation of
PI3K or the alternative NF-B pathways in pediatric relative to
adult GCB DLBCL.
Genome-wide miRNA expression profiling demonstrated dis-
tinct expression profiles for mDLBCL and mBL patients. Pediatric
and adult cases, including the reclassified cases, were indistinguish-
able by miRNA expression profiling, further supporting the close
relationship between adult and pediatric tumors (Figure 1C).
One-third of mDLBCL cases also exhibited high expression of
many of the miRNA characteristically expressed by BL. Many of
these miRNAs are contributed by the miR17	92 cluster that is
up-regulated by MYC and certain other transcription factors, such
as E2F1.42 These may represent mDLBCL cases with higher
expression of MYC and/or other factors that up-regulate miR17	92.
Segregation of mDLBCL into distinct subgroups by miRNA
expression has been previously reported, with marked differences
in MYC-regulated miRNAs between groups.22 Consistent with
previous reports,20 a number of miRNAs prominently repressed in
mBL relative to mDLBCL were found, including miR-22, 23a, 29a,
29b, 29c, 34a, 125b, 150, 155, and 342. Some of these are known
MYC targets,43 and their repression is probably related to high
MYC activity. However, this group of miRNAs tends not to show
the marked repression, even in mDLBCL cases with moderate high
expression of miRs up-regulated in BL. It is possible that down-
regulating the MYC miRNA targets have different requirements
that are not present in the mDLBCL, so these miRs remain elevated
in these cases (MYC needs corepressors to repress gene expression
and inhibitors of MYC may also be present to modulate its
activities). In the DLBCL signature, many of the highly expressed
miRNAs were previously reported to be differentially expressed
between DLBCL and GCB cells, with high miR-222 expression
correlating with poor overall and progression-free survival.21 High
miR-125b expression may have functional relevance in DLBCL
through down-regulation of PRDM1 expression.21 Diminished
miR-155 expression in BL43 and elevated miR-155 expression in
DLBCL21 have been reported and were found to differentiate these
2 entities in the present study. Characterization of the targets of the
differentially expressed miRNAs may further aid in the classifica-
tion of these 2 entities and in understanding the different biologies.
A second aim of this study was to identify genetic aberrations in
pediatric mDLBCL using high-resolution array comparative
genomic hybridization, and to compare these alterations with those
previously found in adult tumors because such a comparison has
not previously been reported. Poirel et al reported karyotype
abnormalities in pediatric DLBCL treated on the FAB LMB
96 trial.34 In that report, Poirel et al34 reported1q, del(13q),7q,
der(3q), der(9p), del(17p), der(18q), 12q, der (11q), and del(6q),
in children and adolescents with DLBCL. Similarities with the
current array CGH study were demonstrated with losses at 3q and
6q and gains at 1q and 12q. However, the current array CGH study
was significantly more precise in identifying many more gains and
losses compared with the previous karyotype study in pediatric
DLBCL.34 Specific aberrations reported in adult DLBCL were also
found in the pediatric cases, including gain of the 2p15 REL locus
reported in PMBL; gain of 12q15, enriched in the GCB subtype of
adult DLBCL; and gain of 19q13.2 and loss of 6q21, enriched in
the ABC subtype of adult DLBCL.35 Our analysis was more
focused on the GCB subtype because it constitutes the majority of
pediatric DLBCL. Two novel deletions were found in the pediatric
cases: 4p14 and 19q13.32. The 19q13.32 locus harbors the
BAX and BBC3 tumor suppressor genes. Whereas deletion of
chromosome 4 and the 4p arm has been reported in lymphoma, a
minimal region has not been delineated. Deletion of 4p14 was
resolved to approximately 283 kb in this study. The RHOH gene in
this interval is expressed in T and B cells and is required for
lymphocyte receptor signaling.44 RHOH is also a target of aberrant
somatic hypermutation in B cells in DLBCL and other B-cell
leukemias and lymphomas.45 Expression of the APBB2 gene was
significantly diminished in the 4p14 deleted cases relative to
nondeleted cases. Consistent with a tumor suppressor role, APBB2
Table 5. Locus-specific impact of DNA CN on gene expression for candidate genes within select MCRs
Cytoband Locus description Genes*
Gains
1q21.1 MCL1 OTUD7B PIAS3 BCL9 NOTCH2NL
2p15 Amplified in PMBL35 ACTR2 PELI1 SLC1A4 REL BCL11A
3q21.3 CNBP GATA2 MCM2 PIK3R4
3q27.3 BCL6 RFC4 ST6GAL1 TBCCD1
11q13.1 BBS1 ANKRD13D RELA ZNHIT2 CCND1
12q15 Adult GCB35 FRS2 RAB3IP IFNG MDM1 MDM2
16p11.2 Novel in pediatric DLBCL FUS MAZ BCL7C CD19 NFATC2IP
19q13.2 Adult ABC35 AKT2 LYPD4 PAK4 CD79A NFKBIB
Losses
2q13 SEPT10 BCL2L11
4p14 Novel in pediatric DLBCL APBB2 RHOH TLR1/6/10
6q21 Adult ABC35 ATG5 AIM1 FOXO3 LIN28B PRDM1
6q23.3 HBS1L BCLAF1 PERP IFNGR1 TNFAIP3
12q24.31 RHOF BCL7A DIABLO
16p11.2 TAOK2 NFATC2IP BCL7C CD19 TP53TG3
19p13.3 RFX2 EBI3 TNFAIP8L1 TNFSF14 TNFSF9
19q13.32 Novel in pediatric DLBCL BAX BBC3 BCL3 IRF2BP1
*Genes highlighted in bold showed a significant correlation between gene expression and gene CN. Locus description annotates MCR in the pediatric cases that were
either novel or that have been previously reported to be enriched in specific DLBCL subtypes.
3764 DEFFENBACHER et al BLOOD, 19 APRIL 2012  VOLUME 119, NUMBER 16
  
is proapoptotic and a regulator of NF-B, p53, and WWOX,46
suggesting a potential functional role in lymphomagenesis.
There have been many discussions regarding the reasons
underlying the better prognosis of pediatric versus adult aggressive
B-cell lymphomas,3,32 be related to the intensive chemotherapy
regimens generally used in childhood cases, to age-related factors,
or to intrinsic differences in the biology between pediatric and adult
tumors. We have demonstrated the predominance of the GCB
subgroup in pediatric mDLBCL, which may partly explain the
better prognosis, in particular for tumors not expressing BCL2.47
Although pediatric BL and DLBCL were found to be similar at the
molecular level compared with the corresponding adult tumors, we
identified subtle differences in gene expression and genetic altera-
tions in this study, suggesting underlying differences in tumor
biology between childhood and adult cases. Some genetic abnor-
malities seem to be unique to the pediatric mDLBCL (4p14,
19q13.32, 16p11.2), and elucidation of the underlying target
genes may provide insight into factors that may modulate outcome.
However, we are uncertain of their significance in influencing
survival at this time. Further studies, such as next-generation
sequencing, may help to answer these important questions.
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Supplemental Table S1. Differentially Expressed Genes using SAM (FDR<0.1) between Pediatric (n = 13) and Adult (n = 51) GCB 
DLBCL 
 
 
Probe set 
Fold-Change 
Ped:Adult Gene symbol Description 
219753_at -5.7 STAG3 stromal antigen 3 
238870_at -5.4 KCNK9 potassium channel, subfamily K, member 9 
217418_x_at -5.0 MS4A1 (CD20) membrane-spanning 4-domains, subfamily A, member 1 
217818_s_at -5.0 ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 
206181_at -3.9 SLAMF1 signaling lymphocytic activation molecule family member 1 
214452_at -3.7 BCAT1 branched chain aminotransferase 1, cytosolic 
210895_s_at -3.7 CD86 CD86 molecule 
228058_at -3.7 ZG16B zymogen granule protein 16 homolog B (rat) 
225723_at -3.6 C6orf129 chromosome 6 open reading frame 129 
223625_at -3.6 FAM126A family with sequence similarity 126, member A 
228415_at -3.5 AP1S2 adaptor-related protein complex 1, sigma 2 subunit 
243364_at -3.5 AUTS2 autism susceptibility candidate 2 
200968_s_at -3.4 PPIB peptidylprolyl isomerase B (cyclophilin B) 
206513_at -3.3 AIM2 absent in melanoma 2 
206348_s_at -3.2 PDK3 pyruvate dehydrogenase kinase, isozyme 3 
228116_at -3.2 FLJ39632 hypothetical LOC642477 
203007_x_at -3.2 LYPLA1 lysophospholipase I 
203470_s_at -3.1 PLEK pleckstrin 
1560503_a_at -3.1 LOC100130275 hypothetical protein LOC100130275 
215674_at -3.1 KIAA1659 KIAA1659 protein 
202988_s_at -3.1 RGS1 regulator of G-protein signaling 1 
203923_s_at -3.0 CYBB cytochrome b-245, beta polypeptide 
202961_s_at -2.9 ATP5J2 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2 
205321_at -2.9 EIF2S3 eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa 
235777_at -2.9 ANKRD44 ankyrin repeat domain 44 
221058_s_at -2.9 CKLF chemokine-like factor 
212694_s_at -2.8 PCCB propionyl Coenzyme A carboxylase, beta polypeptide 
222699_s_at -2.8 PLEKHF2 pleckstrin homology domain containing, family F (with FYVE domain) member 2 
223158_s_at -2.8 NEK6 NIMA (never in mitosis gene a)-related kinase 6 
1558143_a_at -2.8 BCL2L11 BCL2-like 11 (apoptosis facilitator) 
222812_s_at -2.7 RHOF ras homolog gene family, member F (in filopodia) 
202278_s_at -2.7 SPTLC1 serine palmitoyltransferase, long chain base subunit 1 
225772_s_at -2.7 C12orf62 chromosome 12 open reading frame 62 
214639_s_at -2.7 HOXA1 homeobox A1 
208467_at -2.6 KLF12 Kruppel-like factor 12 
214773_x_at -2.6 TIPRL TIP41, TOR signaling pathway regulator-like (S. cerevisiae) 
222508_s_at -2.6 ARGLU1 arginine and glutamate rich 1 
224443_at -2.6 C1orf97 chromosome 1 open reading frame 97 
218357_s_at -2.6 TIMM8B translocase of inner mitochondrial membrane 8 homolog B (yeast) 
225065_x_at -2.6 NCRNA00188 non-protein coding RNA 188 
205013_s_at -2.6 ADORA2A adenosine A2a receptor 
1554193_s_at -2.5 MANEA mannosidase, endo-alpha 
209364_at -2.5 BAD BCL2-associated agonist of cell death 
215346_at -2.5 CD40 CD40 molecule, TNF receptor superfamily member 5 
233124_s_at -2.4 ECHDC1 enoyl Coenzyme A hydratase domain containing 1 
235244_at -2.4 CCDC58 coiled-coil domain containing 58 
200002_at -2.4 RPL35 ribosomal protein L35 
1559747_at -2.4 SPG11 spastic paraplegia 11 (autosomal recessive) 
226090_x_at -2.4 RABL3 RAB, member of RAS oncogene family-like 3 
208490_x_at -2.3 HIST1H2BF histone cluster 1, H2bf 
200834_s_at -2.3 RPS21 ribosomal protein S21 
204350_s_at -2.3 MED7 mediator complex subunit 7 
208447_s_at -2.3 PRPS1 phosphoribosyl pyrophosphate synthetase 1 
205967_at -2.2 HIST1H4C histone cluster 1, H4c 
217691_x_at -2.2 SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid transporter 4) 
239114_at -2.2 SERGEF secretion regulating guanine nucleotide exchange factor 
206562_s_at -2.2 CSNK1A1 casein kinase 1, alpha 1 
221563_at -2.2 DUSP10 dual specificity phosphatase 10 
210733_at -2.2 TRAM1 translocation associated membrane protein 1 
225309_at -2.2 PHF5A PHD finger protein 5A 
222837_s_at -2.2 NARG1 NMDA receptor regulated 1 
217714_x_at -2.2 STMN1 stathmin 1 
208092_s_at -2.1 FAM49A family with sequence similarity 49, member A 
209204_at -2.1 LMO4 LIM domain only 4 
1554780_a_at -2.1 PHTF2 putative homeodomain transcription factor 2 
243492_at -2.1 THEM4 thioesterase superfamily member 4 
209743_s_at -2.1 ITCH itchy E3 ubiquitin protein ligase homolog (mouse) 
200025_s_at -2.1 RPL27 ribosomal protein L27 
217960_s_at -2.1 TOMM22 translocase of outer mitochondrial membrane 22 homolog (yeast) 
203034_s_at -2.1 RPL27A ribosomal protein L27a 
203025_at -2.0 ARD1A ARD1 homolog A, N-acetyltransferase (S. cerevisiae) 
200099_s_at -2.0 RPS3A ribosomal protein S3A 
205145_s_at -2.0 MYL5 myosin, light chain 5, regulatory 
200012_x_at -2.0 RPL21 ribosomal protein L21 
223682_s_at -2.0 EIF1AD eukaryotic translation initiation factor 1A domain containing 
229751_s_at -2.0 PUS7L pseudouridylate synthase 7 homolog (S. cerevisiae)-like 
200095_x_at -2.0 RPS10 ribosomal protein S10 
220669_at -2.0 OTUD4 OTU domain containing 4 
200026_at -2.0 RPL34 ribosomal protein L34 
200032_s_at -2.0 RPL9 ribosomal protein L9 
233746_x_at -2.0 C15orf63 chromosome 15 open reading frame 63 
200674_s_at -2.0 RPL32 ribosomal protein L32 
213941_x_at -1.9 RPS7 ribosomal protein S7 
1554342_s_at -1.9 HELQ helicase, POLQ-like 
222600_s_at -1.9 UBA6 ubiquitin-like modifier activating enzyme 6 
204097_s_at -1.9 RBMX2 RNA binding motif protein, X-linked 2 
204833_at -1.8 ATG12 ATG12 autophagy related 12 homolog (S. cerevisiae) 
227086_at -1.8 C22orf39 chromosome 22 open reading frame 39 
202905_x_at -1.8 NBN nibrin 
233819_s_at -1.8 RNF160 ring finger protein 160 
208695_s_at -1.8 RPL39 ribosomal protein L39 
211074_at -1.8 FOLR1 folate receptor 1 (adult) 
223584_s_at -1.8 KBTBD2 kelch repeat and BTB (POZ) domain containing 2 
217981_s_at -1.8 FXC1 fracture callus 1 homolog (rat) 
210048_at -1.8 NAPG N-ethylmaleimide-sensitive factor attachment protein, gamma 
201049_s_at -1.8 RPS18 ribosomal protein S18 
219484_at -1.8 HCFC2 host cell factor C2 
216954_x_at -1.8 ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 
213875_x_at -1.7 C6orf62 chromosome 6 open reading frame 62 
203677_s_at -1.7 TARBP2 TAR (HIV-1) RNA binding protein 2 
225106_s_at -1.7 OGFOD1 2-oxoglutarate and iron-dependent oxygenase domain containing 1 
203610_s_at -1.7 TRIM38 tripartite motif-containing 38 
226351_at -1.6 NSUN4 NOL1/NOP2/Sun domain family, member 4 
226727_at -1.6 CISD3 CDGSH iron sulfur domain 3 
211537_x_at -1.5 MAP3K7 mitogen-activated protein kinase kinase kinase 7 
225172_at 1.5 CRAMP1L Crm, cramped-like (Drosophila) 
241727_x_at 1.6 DHFRL1 dihydrofolate reductase-like 1 
204906_at 1.8 RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 
215790_at 1.8 AJAP1 adherens junctions associated protein 1 
65718_at 1.9 GPR124 G protein-coupled receptor 124 
227204_at 1.9 PARD6G par-6 partitioning defective 6 homolog gamma (C. elegans) 
47069_at 2.0 PRR5 proline rich 5 (renal) 
1552770_s_at 2.1 ZNF563 zinc finger protein 563 
238593_at 2.2 C11orf80 chromosome 11 open reading frame 80 
219596_at 2.2 THAP10 THAP domain containing 10 
232102_at 2.3 METTL6 methyltransferase like 6 
216912_at 2.4 ARHGEF4 Rho guanine nucleotide exchange factor (GEF) 4 
235616_at 2.5 TSHZ2 teashirt zinc finger homeobox 2 
235635_at 2.6 ARHGAP5 Rho GTPase activating protein 5 
205019_s_at 2.6 VIPR1 vasoactive intestinal peptide receptor 1 
244655_at 2.7 LOC100132798 similar to hCG1774772 
201906_s_at 2.8 CTDSPL CTD(carboxy-terminal domain,RNA pol II,polypeptide A) small phosphatase-like 
1556062_at 2.8 RPP30 ribonuclease P/MRP 30kDa subunit 
201596_x_at 2.9 KRT18 keratin 18 
205606_at 2.9 LRP6 low density lipoprotein receptor-related protein 6 
239153_at 2.9 HOTAIR hox transcript antisense RNA (non-protein coding) 
223672_at 3.0 SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1 
236094_at 3.0 TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) 
224310_s_at 3.1 BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 
229084_at 3.2 CNTN4 contactin 4 
207995_s_at 3.5 CLEC4M C-type lectin domain family 4, member M 
1553808_a_at 4.8 NKX2-3 NK2 transcription factor related, locus 3 (Drosophila) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table S2. Differentially Expressed Genes between Pediatric (n = 45) and Adult (n = 17) mBL 
 
 
Probe set 
Fold-Change 
Ped:Adult Gene symbol Description 
212589_at -4.6 RRAS2 related RAS viral (r-ras) oncogene homolog 2 
1553499_s_at -4.5 
SERPINA9 
(GCET1) serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 
205081_at -3.7 CRIP1 cysteine-rich protein 1 (intestinal) 
219667_s_at -3.6 BANK1 B-cell scaffold protein with ankyrin repeats 1 
209131_s_at -3.6 SNAP23 synaptosomal-associated protein, 23kDa 
206632_s_at -3.4 APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 
203771_s_at -3.3 BLVRA biliverdin reductase A 
221142_s_at -3.0 PECR peroxisomal trans-2-enoyl-CoA reductase 
203642_s_at -2.9 COBLL1 COBL-like 1 
223136_at -2.6 AIG1 androgen-induced 1 
219696_at -2.3 DENND1B DENN/MADD domain containing 1B 
225735_at 2.0 ANKRD50 ankyrin repeat domain 50 
221997_s_at 2.0 MRPL52 mitochondrial ribosomal protein L52 
215011_at 2.1 SNHG3 small nucleolar RNA host gene 3 (non-protein coding) 
209826_at 2.2 PPT2 palmitoyl-protein thioesterase 2 
214600_at 2.2 TEAD1 TEA domain family member 1 (SV40 transcriptional enhancer factor) 
232821_at 2.2 GTSF1L gametocyte specific factor 1-like 
205432_at 2.4 OVGP1 oviductal glycoprotein 1, 120kDa 
230424_at 2.4 C5orf13 chromosome 5 open reading frame 13 
237905_at 2.4 KRT25 keratin 25 
227512_at 2.5 MEX3A mex-3 homolog A (C. elegans) 
229792_at 2.6 KLHL17 kelch-like 17 (Drosophila) 
219491_at 2.6 LRFN4 leucine rich repeat and fibronectin type III domain containing 4 
221558_s_at 2.6 LEF1 lymphoid enhancer-binding factor 1 
1566737_at 2.6 hCG_2036596 hCG2036596 
1564254_at 2.6 KY kyphoscoliosis peptidase 
1556425_a_at 2.6 LOC284219 hypothetical protein LOC284219 
239317_at 2.7 CEACAM21 carcinoembryonic antigen-related cell adhesion molecule 21 
1553443_at 2.7 C8orf54 chromosome 8 open reading frame 54 
206752_s_at 2.7 DFFB DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase) 
1556609_at 2.7 LOC401098 hypothetical LOC401098 
239188_at 2.7 PPP2R3C protein phosphatase 2 (formerly 2A), regulatory subunit B'', gamma 
230708_at 2.7 PRICKLE1 prickle homolog 1 (Drosophila) 
213283_s_at 2.7 SALL2 sal-like 2 (Drosophila) 
239980_at 2.8 C22orf28 chromosome 22 open reading frame 28 
233100_at 2.8 EEPD1 endonuclease/exonuclease/phosphatase family domain containing 1 
1555353_at 2.8 LRP1 low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 
237891_at 2.8 MDM2 Mdm2 p53 binding protein homolog (mouse) 
1553602_at 2.8 MUCL1 mucin-like 1 
233742_at 2.9 C16orf68 chromosome 16 open reading frame 68 
234221_at 2.9 BCAS1 breast carcinoma amplified sequence 1 
242957_at 2.9 VWCE von Willebrand factor C and EGF domains 
206404_at 3.0 FGF9 fibroblast growth factor 9 (glia-activating factor) 
207199_at 3.2 TERT telomerase reverse transcriptase 
1562484_at 3.2 FLJ35848 hypothetical protein FLJ35848 
1559688_at 3.2 LOC400581 GRB2-related adaptor protein-like 
240088_at 3.2 PDE5A phosphodiesterase 5A, cGMP-specific 
226610_at 3.5 CENPV centromere protein V 
1553185_at 3.5 RASEF RAS and EF-hand domain containing 
214265_at 3.5 ITGA8 integrin, alpha 8 
209493_at 3.7 PDZD2 PDZ domain containing 2 
210063_at 3.7 SARDH sarcosine dehydrogenase 
231743_at 3.7 WNT3 wingless-type MMTV integration site family, member 3 
217520_x_at 4.0 LOC731884 similar to programmed cell death 6 interacting protein 
224918_x_at 4.2 MGST1 microsomal glutathione S-transferase 1 
227377_at 4.4 IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 
207961_x_at 4.4 MYH11 myosin, heavy chain 11, smooth muscle 
214131_at 4.6 CYorf15B chromosome Y open reading frame 15B 
212504_at 5.3 DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 
213920_at 5.6 CUX2 cut-like homeobox 2 
237461_at 7.7 NLRP7 NLR family, pyrin domain containing 7 
218824_at 8.3 PNMAL1 PNMA-like 1 
204914_s_at 30.3 SOX11 SRY (sex determining region Y)-box 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Supplemental Table S3. Differentially expressed miRNA between molecularly classified BL (n=31) and DLBCL (n=58) determined 
by SAM analysis (FDR = 0.1) 
 
 
miRNA ID 
Fold change 
BL:DLBCL 
Parametric        
p-value 
miR-296-3p  5.0 1.5E-04 
miR-339-5p  2.9 1.4E-05 
miR-128  2.4 2.1E-05 
miR-296-5p  2.8 6.1E-06 
miR-597  2.2 1.0E-07 
miR-130b  2.3 5.7E-06 
miR-92a  2.6 3.1E-05 
miR-18a  3.7 1.0E-07 
miR-18b  3.7 1.0E-07 
miR-19a  3.6 1.0E-07 
miR-20b  3.8 1.0E-07 
miR-17  3.6 1.0E-07 
miR-106a  3.4 1.0E-07 
miR-19b  2.9 1.0E-07 
miR-20a  3.3 2.0E-07 
miR-125b  -2.1 2.1E-04 
miR-99a  -1.9 5.8E-03 
miR-100  -2.0 3.8E-03 
miR-199a-3p  -2.1 6.8E-06 
miR-455-5p  -2.5 8.5E-06 
miR-29c  -2.1 1.7E-04 
miR-29a  -2.0 3.9E-04 
miR-29b  -2.6 5.7E-05 
miR-23a  -3.0 1.2E-06 
miR-22  -2.5 4.1E-06 
miR-34a  -2.2 1.4E-04 
miR-21  -2.7 4.0E-06 
miR-340  -2.0 4.4E-04 
miR-150  -2.8 1.6E-03 
miR-342-5p  -7.0 2.0E-06 
miR-222  -3.0 4.3E-05 
miR-146a  -2.7 9.5E-05 
miR-155  -7.5 1.0E-07 
miR-135b  -3.9 3.0E-04 
miR-708  -2.4 1.4E-04 
 
Supplemental Table S4. Complete list of minimal common regions (MCR) of gain (n=16) and loss (n=18) observed in two or more pediatric mDLBCL 
specimens  
 
(A) Gains 
 
Cytoband Start (bp) End (bp) # 
cases 
# 
genes 
MCR Genes*
1q21.1 143711033 147978058 5 36 ACP6, ANKRD34, ANKRD35,BCL9, CD160,  CHD1L, FAM108A3, FMO5, GJA5, GJA8, 
GPR89A,  GPR89B, GPR89C, HFE2,ITGA10, LIX1L,  LOC728912, NBPF10, NBPF11, 
NBPF14, NBPF15, NBPF16  NOTCH2NL,NUDT17,PDE4DIP, PDZK1, PEX11B, PIAS3, 
POLR3C,  POLR3GL, PPIAL4, PRKAB2, RBM8A, SEC22B, TXNIP, ZNF364 
2p15 63326947 63429296 3 1 LOC51057 
   
2p11.2 86874328 87344242 5 5 CD8B,RGPD1,RGPD2,PLGLB1,PLGLB2 
3q21.3 130316240 130470589 3 4 RAB43,COPG,ISY1,CNBP 
  
3q27.3 188988884 189230771 3 0   
5p15.33 771021 874726 3 1 ZDHHC11 
5q35.3 177317148 177444039 3 3 PROP1, LOC653316,LOC653314 
11q13.1 66089648 66917537 9 23 ADRBK1,ANKRD13D ,C11orf80,CCDC87,CCS,CLCF1,CTSF, FBXL11,KIAA1394, 
LRFN4, PC,POLD4,PPP1CA,RAD9A,RBM14, RBM4, RBM4B, RCE1, RHOD, SPTBN2, 
SSH3, SYT12, TBC1D10C 
12q13.11 46451025 46652716 5 4 FLJ20489,HDAC7A,VDR,TMEM106C 
12q15 68166895 68283401 5 2 FRS2,CCT2  
12q21.32 85646042 85784777 3 1 MGAT4C 
12q24.33 131822017 132287718 3 9 CHFR, GOLGA3, KIAA0692, ZNF10, ZNF140, ZNF26, ZNF268, ZNF605,ZNF84 
16q22.1 66955933 67070888 3 1 SMPD3 
17q21.33 45184550 45299835 6 3 FAM117A, MYST2,TAC4 
19q13.2 45922835 45961895 4 3 ITPKC,C19orf54,SNRPA  
20q13.33 61628090 61776652 5 7 PTK6, SRMS, C20orf195, PRIC285, GMEB2, STMN3, RTEL1 
 
(B) Losses 
 
Cytoband Start (bp) End (bp) # 
cases 
# 
genes 
MCR Genes* 
2q37.1 233408623 233535919 3 3
4 2
6 6
2 2
3 35
4 7
2 4
3 4
6 2
3 14
4 3
3 2
4 16
5 17
6 31
8 2
8 6
4 10
TNRC15,NGEF,UNQ830 
2q13 109614467 109814503 SH3MD4,SEPT10 
3q29 197759362 197965421 WDR53,FBXO45,LRRC33,C3orf34,PIGX,PAK2 
4p14 40025322 40308822 CHRNA9,FLJ20273 
6q21 107466427 111833304 AMD1, ARMC2, BXDC1, C6orf182, C6orf199, C6orf203, CD164,CDC2L6, CDC40, DDO, 
FIG4, FLJ25791, FLJ42177,FOXO3, GPR6, GTF3C6,KIAA1553, KIAA1919, LACE1, 
MICAL1, NR2E1, OSTM1, PDSS2,PPIL6,REV3L,SCML4, SEC63,SESN1,  SLC16A10, 
SLC22A16,  SMPD2, SNX3, SOBP, WASF1, ZBTB24 
6q23.3 137402985 138565621 IL20RA, IL22RA2,IFNGR1, OLIG3, TNFAIP3, PERP, KIAA1244 
7p22.1 4783100 4941029 KIAA0415, RADIL, PAPOLB, MMD2 
7q22.1 100419510 100586851 MUC17, TRIM56, SERPINE1, AP1S1 
8q21.13 81579330 81665747 ZBTB10, LOC389672 
8q24.3 145327191 145654320 ADCK5, BOP1, C8orf30A, CPSF1, DGAT1, FBXL6, GPR172A, HSF1, KIAA1833, NFKBIL2, 
SCRT1, SCXB, SLC39A4, VPS28, 
11p15.5 878150 1053247 CHID1,AP2A2,MUC6 
12q24.31 122148808 122217919 PITPNM2,MPHOSPH9, RHOF 
16p11.2 29580704 29926001 ASPHD1, C16orf53,C16orf54,CCDC95, CDIPT, DOC2A,HIRIP3,KCTD13,LOC124446,MAZ, 
MVP, PRRT2, QPRT, SEZ6L2, SPN, TAOK2 
19p13.3 5605449 5951313 CAPS,DUS3L, FUT3, FUT5, FUT6, HSD11B1L, LONP1, MGC24975, NDUFA11, NRTN, 
P117, RANBP3, RFX2, RPL36,  SAFB, TMEM146, VMAC 
19p13.2 12502060 13115875 ASNA1, BEST2, BTBD14B, C19orf43, C19orf56, CALR, ,DAND5, DHPS, DNASE2, FARSA, 
FBXW9,GADD45GIP1,GCDH, HOOK2,JUNB,KLF1,LYL1,MAN2B1,MAST1,MORG1,NFIX, 
PRDX2,RAD23A, RNASEH2A,RTBDN,SYCE2,TNPO2,TRMT1,ZNF490,ZNF564,ZNF791, 
19q13.12 42133205 42312088 ZNF568,ZNF420 
19q13.2 46997883 47120607 CEACAM3, LYPD4,DMRTC2,RPS19,CD79A, ARHGEF1 
19q13.32 51790267 52210724 CALM3, PTGIR, GNG8,DACT3,PRKD2,STRN4, FKRP,SLC1A5,AP2S1,GRLF1 
 
* MCR genes lists all genes residing in an MCR by RefSeq Gene Symbol. Genes listed in bold demonstrated a significant correlation between gene 
expression and DNA copy number as determined by one-sided t-test (p < 0.05).
Supplemental Figure Legends 
 
Figure S1. Overall survival of pediatric and adult patients according to treatment and molecular 
diagnosis. Pediatric patients are defined as ≤ 20 years of age. Pediatric DLBCL (black) and Pediatric 
BL (blue) include all pediatric cases with available clinical data. Adult DLBCL are stratified according 
to CHOP (yellow) or R-CHOP (aqua) treatment. Pediatric DLBCL CHOP (pink) includes 6 pediatric 
cases younger than 20 years who were treated similar to adult DLBCL with a CHOP-like regimen. 
 
Figure S2. Differential gene expression between adult (n = 51) and pediatric (n = 13) molecularly-
defined GCB DLBCL, as determined by SAM analysis (FDR = 0.1).  
 
Figure S3. Differential gene expression between adult (n = 17) and pediatric (n = 45) mBL, as 
determined by SAM analysis (FDR = 0.1).  
 
Figure S4. Chromosomal imbalances in pediatric mDLBCL according to molecular subtype. 
Genomewide copy number alterations (CNA) are shown as gains to the right and losses to the left of 
each chromosome. CNA are color-coded according to the molecular classification of DLBCL subtype.   
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Figure S1. Overall survival in pediatric and adult patients with lymphoma by molecular diagnosis
Figure S2. Differential gene expression between adult and pediatric mGCB by SAM analysis
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Figure S3. Differential gene expression between adult and pediatric mBL by SAM analysis
Figure S4. Chromosomal imbalances in pediatric mDLBCL
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